Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > COMMENTARY
COMMENTARY
-
COMMENTARY/Reform of Ethical Drug Distribution Practices
September 1, 2008
-
COMMENTARY/Gov't to Cut Social Security Spending by \220 Bil by Promoting Use of Generics
August 25, 2008
-
COMMENTARY/Development Race for RNAi Therapeutics Heating Up in Japan
August 4, 2008
-
COMMENTARY 4 articles
July 28, 2008
-
COMMENTARY/Industry Needs More Creative Thinking: NHI Pricing System Reform
July 21, 2008
-
COMMENTARY/Will Fiscal Rehabilitation Policy Be Maintained?
July 7, 2008
-
COMMENTARY/Daiichi Sankyo Surprises the World by Announcing Acquisition of Ranbaxy
June 30, 2008
-
Pharmaceutical Partnerships in Japan for Regulatory and Commercial Success
June 30, 2008
-
COMMENTARY 4 articles
June 9, 2008
-
COMMENTARY/Shaking Pharmaceutical Administration System
May 19, 2008
-
COMMENTARY/Personnel Strategy -New Graduates or Work-Ready MRs?
April 21, 2008
-
COMMENTARY/Industry-Academia Cooperation Essential for Practical Use of iPS Cells
April 21, 2008
-
COMMENTARY/Improvement of Drug Distribution Business Practices Goes into Crucial Stretch
April 14, 2008
-
COMMENTARY/Mr Kodama Owes His Sweeping Victory to Members' Desire for Change: JPA
March 31, 2008
-
COMMENTARY/Most Mainstay Products Avoid Deep Price Cuts in FY2008 NHI Price Revision
March 31, 2008
-
Methodologic Issues in the Clinical Trial Study of Depression
March 24, 2008
-
COMMENTARY/Major Wholesalers vs Hansha Competition to Intensify on Growing Market for Generics
March 3, 2008
-
COMMENTARY/Preparations for New OTC Drug Marketing System Enter Final Stage
March 3, 2008
-
COMMENTARY/Japan Needs to Create Attractive "Stadium for Drug Discovery" and Invite Top-Level Players
February 25, 2008
-
COMMENTARY/Revision of Medical Fees May Increase Use of Drugs for Stroke, Mental Illnesses, Cancer
February 11, 2008
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…